Spyre Therapeutics, Inc.
Every calculator, already run for SYRE
Open the full toolkit →You have the numbers on SYRE. Get the argument.
A written report on which of these readings actually decide the outcome for Spyre Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
17 analysts covering SYREAnalyst Price Target Disagreement for Spyre Therapeutics, Inc.
Wall Street's bull case implies +44% from the current price; the bear case implies +7%. A 37% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for SYRE
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4…
SYRE — frequently asked
Is SYRE a buy right now?
Wall Street's consensus rating on Spyre Therapeutics, Inc. is Strong Buy across 17 analysts, with a mean price target of $119.71 (+32% vs. the current $90.36). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is SYRE's next earnings date?
Spyre Therapeutics, Inc. is next scheduled to report earnings around Nov 3, 2026. A full SYRE research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Spyre Therapeutics, Inc.?
Analysts covering Spyre Therapeutics, Inc. (SYRE) range from a bear-case target of $97.00 to a bull-case high of $130.00, with a mean consensus target of $119.71 across 14 analysts. The spread of $33.00 (37% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Spyre Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Spyre Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full SYRE research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Spyre Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.